A Proof-of-Concept, Double-blind, Randomized, Placebo-controlled Study of Ganaxolone in Posttraumatic Stress Disorder.

Trial Profile

A Proof-of-Concept, Double-blind, Randomized, Placebo-controlled Study of Ganaxolone in Posttraumatic Stress Disorder.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Ganaxolone (Primary)
  • Indications Post-traumatic stress disorders
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Marinus Pharmaceuticals
  • Most Recent Events

    • 01 Aug 2017 Based on the observed general safety of ganaxolone, the upper end of the age range for study eligibility was increased from 55 to 65 years on February 22, 2013, after which an additional 18 participants included in the modified intent-to-treat sample were recruited.
    • 20 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Jan 2014 Planned End Date changed from 1 Feb 2014 to 1 Mar 2014, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top